

THAT WHICH IS CLAIMED

843₅

A method for treating or preventing erectile dysfunction in a patient, said method comprising administering to said patient a therapeutically effective amount of a growth factor, wherein said growth factor is selected from the group consisting of FGF, EGF, PDGF, VEGF, and TGF.

- 2. The method of claim 1, wherein said growth factor is administered to one or more blood vessels in said patient.
 - 3. The method of claim 2, wherein said growth factor is FGF.

10 Sut

- 4. The method of claim 3, wherein said FGF is FGF-2.
- 5. The method of claim 4, wherein said FGF-2 is a recombinant molecule.

8/6

20

6. The method of claim 5, wherein said FGF-2 comprises the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or a biologically active fragment or mutein thereof.


7. The method of claim 6, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about .008 mg to about 5.1 mg.

The method of claim 7, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about 0.3 mg to about 3.5 mg.

9. The method of claim 7, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about .008 mg to about 5.1 mg.

15

20



- The method of claim 6, wherein said therapeutically effective amount of
 said FGF-2 or said biologically active fragment or mutein thereof is about 0.2 μg/kg to
 about 36 μg/kg.
 - 12. The method of claim 11, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about 0.2 μ g/kg to about 2 μ g/kg.
- 10 13. The method of claim 11, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about 2 μ g/kg to about 20 μ g/kg.
 - 14. The method of claim 11, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about 20 μ g/kg to about 36 μ g/kg.
 - 15. The method of claim 1, wherein said growth factor is administered by transmural delivery.

A method for improving erectile function in a mammal, said method comprising delivering at a target site in said mammal in a therapeutically effective amount a pharmaceutical composition, said composition comprising a growth factor selected from the group consisting of FGF, EGF, PDGF, VEGF, and TGF and a pharmaceutically acceptable carrier.

17. The method of claim 16, wherein said growth factor is administered to one or more blood vessels in said patient.

15

18. The method of claim 17, wherein said growth factor is FGF.

Sufi

- 19. The method of claim 18, wherein said FGF is FGF-2.
- 20. The method of claim 19, wherein said FGF-2 is a recombinant molecule.

The method of claim 19, wherein said FGF-2 comprises the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or a biologically active fragment or mutein thereof.

- 22. The method of claim 21, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about .008 mg to about 5.1 mg.
- 10 23. The method of claim 22, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about 0.3 mg to about 3.5 mg.
 - 24. The method of claim 22, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about .008 mg to about 5.1 mg.
 - 25. The method of claim 22, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about .008 mg to about 5.1 mg.
- 26. The method of claim 21, wherein said therapeutically effective amount of
 20 said FGF-2 or said biologically active fragment or mutein thereof is about 0.2 μg/kg to
 about 36 μg/kg.
 - 27. The method of claim 26, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about $0.02 \mu g/kg$ to about $2 \mu g/kg$.

- 28. The method of claim 26, wherein said therapeutically effective amount of said FGF-2 or said biologically active fragment or mutein thereof is about 2 μ g/kg to about 20 μ g/kg.
- The method of claim 26, wherein said therapeutically effective amount of
 said FGF-2 or said biologically active fragment or mutein thereof is about 20 μg/kg to
 about 36 μg/kg.